Televitas 3A

Your universal e-health ecosystem
€44,000
total amount raised in round
176%
  • Eligible for a tax reduction
Campaign Closed

Revenue & Business Model


Televitas operates a hybrid model that combines recurring revenue streams with flexible project-based income. This structure supports both financial resilience and scalability as the company targets healthcare institutions, employers, and insurers.


Primary Revenue Streams

  • Platform Licensing

    • Pro version for hospitals and large providers with advanced analytics and AI tools.
    • Light version for care centers and smaller institutions.

  • Communication Hub (Hardware-as-a-Service)

    • Offered via monthly subscription for seamless integration into home and care settings.

  • Data Connectors

    • Enable integration with wearables, apps, and sensors.
    • Delivered through scalable, usage-based subscriptions.


Secondary Revenue Streams

  • Digital Pricing Service : Transaction-based revenue tied to automated billing and reimbursement of remote care.

  • Consulting & Integration Services : Time-and-material based support for platform implementation in healthcare environments.

  • Custom Data Services : Development of predictive AI models and tailored reporting, charged per project or daily rate.


Televitas owns 100% of the intellectual property across software, AI models, and hardware components—ensuring control and long-term value capture.





Business Model Logic


Televitas delivers value across four key segments:

  • Healthcare Providers: Integration with EHR systems and real-time data access improve patient outcomes and operational efficiency.
  • Healthcare Professionals: Centralized dashboards help track patient compliance and personalize care.
  • Employers (HR departments): Health monitoring and predictive analytics reduce absenteeism and burnout risk.
  • Insurers: Access to real-time lifestyle and health metrics enables personalized risk models and early interventions.

Each segment is supported by a pricing strategy that blends:

  • Subscription fees (based on users or usage volume)
  • One-time onboarding/integration fees
  • Add-on pricing for advanced analytics, visualizations, or white-labeled services


Scalability & Growth Potential


  • Cloud-native architecture ensures rapid scaling across care institutions, employers, and national borders.
  • Subscription-based income builds predictable, recurring revenue.
  • Consulting and integration deepen customer retention and fuel long-term platform usage.
  • Strategic partnerships with wearable manufacturers, pharma, and public health institutions create additional monetization layers (e.g. licensing, data agreements).


Commercial Traction


A pilot hybrid care project with residential care centers—focused on type 2 diabetes—has already demonstrated ROI:

  • Monthly savings per patient: ~€83
  • Pilot return: ~€413 net per month (10 patients)
  • Full-scale rollout (2,600 patients):

    • Monthly savings: €216,667
    • Televitas cost: €58,200
    • Net benefit: ~€158,000/month

Reimbursement is supported through NIHII codes, digital consultation policies, and partnerships with care groups and regional authorities.


Business plan 5+


Televitas combines the recurring revenue model of a SaaS platform with the real-world urgency of digital healthcare transformation. Backed by public reimbursement frameworks, growing demand for hybrid care, and a mature IP portfolio, it is positioned to:

  • Deliver strong EBITDA growth starting in year 3.
  • Achieve high-margin, scalable revenue through a subscription-first model.
  • Expand internationally with controlled, modular rollouts across public and private health systems.

With proof points in place and market expansion already underway, Televitas offers investors access to a resilient, tech-enabled health platform aligned with macro trends in aging, digitization, and preventive care.






Looking Ahead


  • Expand platform licensing to more care pathways: geriatric, pediatric, chronic care.
  • Launch prevention programs via Health Arena consortium (Q2 2025).
  • Target international markets (NL, EU, US) via existing partnerships and EU health innovation funding.